News Articles
Showing 7690 News Articles-
FILAMENT Wellness AND CYBIN THERAPEUTICS ANNOUNCE Approval FOR Stage II ...
Jan 31, 2022 – Trial to look into the results of Filament's botanical psilocybin drug prospect and Cybin Therapeutics' protocols in managing significant ...
Psilocybin
-
Braxia Scientific Provides Update on Large Proprietary Dataset Expected to Support ...
Jan 31, 2022 – ... on Large Proprietary Dataset Expected to Support Pharmaceutical and Industry Clinical Trials for Ketamine and Psilocybin Drug Development.
Psilocybin / Ketamine
-
filament health and cybin therapeutics announce approval for phase ii clinical trial for depression
Jan 31, 2022 – Trial to investigate the effects of Filament's botanical psilocybin drug candidate and Cybin Therapeutics' protocols in treating major depressive ...
Psilocybin
-
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Q1 2022 Financial Numbers
Jan 31, 2022 – Tryp's psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program is focused on the development of synthetic psilocybin as a new class of ...
Psilocybin
-
UPDATE: Filament Health (FH.NE) Receives Approval From Health Canada for Phase 2 Clinical Trial
Jan 31, 2022 – (CYBN.NE), Cybin Therapeutics is a private therapeutic bioscience company committed to developing psilocybin-assisted therapeutic protocols to treat ...
Psilocybin
-
Braxia Scientific Corp. says it continues psychedelic-based clinical research trials to support ...
Jan 31, 2022 – ... subsidiary has established a growing database with key clinical outcomes for an ongoing clinical trial evaluating psilocybin-assisted therapy.
Psilocybin / Ketamine
-
Q&A with Dr. Tiffany Sauls, psychiatrist providing psychedelic-assisted psychotherapy ...
Jan 31, 2022 – Today, Sauls provides ketamine-assisted psychotherapy at her integrative psychiatry practice in Asheville. The federal Department of Justice's Drug ...
Ketamine / MDMA
-
Jan 31, 2022 – Ketamine infusions will be offered to people with major depressive disorder, post-traumatic stress disorder, postpartum depression, suicidal ideation ...
Ketamine
-
Perceptual studies may explain promising depression treatments - Florida News Times
Jan 31, 2022 – We then tested what happens when we administer small doses of ketamine. Credits: Scott Yu, I. Gauthier, I., MJ Tarr Via Wikimedia Commons.
Ketamine
-
Why Docs are Legitimately Using Ketamine Therapy to Treat Depression - Medical News Bulletin
Jan 31, 2022 – Fortunately for patients suffering from treatment resistant depression, there are alternative treatment options, such as ketamine.
Ketamine
-
Perception study may explain promising depression therapy - UW–Madison News
Jan 31, 2022 – Their study reveals the importance of a specific type of connection between brain cells and may also explain ketamine's promise as a treatment for ...
Ketamine
-
Relieving depression with LSD-like drugs without causing hallucinations | FierceBiotech
Jan 31, 2022 – The hallucination side effect has stalled the use of psychedelics such as LSD and psilocybin from “magic mushrooms” to treat depression.
Psilocybin / LSD
-
Researchers use linguistic analysis to uncover differences between psychedelic drug experiences
Jan 31, 2022 – The sample included 971 reports about psilocybin-containing mushrooms, 671 reports about LSD, 312 reports about DMT, 163 reports about ketamine, ...
Psilocybin / LSD / DMT / Ketamine / Ayahuasca
-
Small Pharma Reports Fiscal Third Quarter 2021 Highlights - GlobeNewswire
Jan 31, 2022 – DMT is a naturally occurring psychedelic tryptamine found in plants and in the brain of mammals. Scientific evidence suggests DMT offers the potential ...
DMT / Tryptamine
-
Pharma to Test if DMT Helps Brain Regain Function Post Stroke - Investorideas.com
Jan 31, 2022 – 27, 2022, representatives of Algernon Pharmaceuticals discussed the use of the psychedelic DMT in stroke sufferers. On the broadcast were Algernon ...
DMT
-
9th Circ. Won't Review DEA Letter On Medical Psilocybin Use - Law360
Jan 31, 2022 – Psilocybin is a hallucinogenic substance obtained from certain mushrooms and is a Schedule I drug under the CSA, per Monday's opinion.
Psilocybin
-
Popular '80s party drug slowly gains respect as PTSD treatment - Global Circulate
Jan 31, 2022 – “MDMA allows you to access these really deep traumatic memories in a way that is not anxiety-provoking,” said Jennifer Mitchell, ...
MDMA
-
Best 2022 Wellness Trend? Tripping at a Psychedelic Retreat - Thrillist
Jan 31, 2022 – From shrooms to ayahuasca, these wellness hotels are tapping into a new way to help mental health with psychedelic micro-dosing.
Ayahuasca / Psilocybin / LSD / MDMA
-
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Market Exclusive
Jan 31, 2022 – Trulieve borrowed additional $75 million at 8%. Key Takeaways; Psychedelic Sector. Awakn filed a patent application for a new class of entactogen-like ...
-
Leafy Tunnel announces the first closing of its medical cannabis and psychedelics fund
Jan 31, 2022 – The investment strategy of the fund focuses on European medical cannabis and global medical psychedelics companies at Seed and Series A stages.
Cannabis
-
Colorado Could See two Psychedelic Ballot Measures in November | Westword
Jan 31, 2022 – Get ready, Colorado voters: Come November, there's a chance you may get to decide on not one psychedelics ballot measure, but two.
Psilocybin
-
Jan 27, 2022
atai Life Sciences
-
Numinus Wellness Inc. Graduates to the OTCQX Best Market
Jan 26, 2022
Numinus
-
Jan 26, 2022
Awakn Life Sciences, Inc.
-
Jan 26, 2022
Filament Health
-
Seattle Legalizes Psychedelics
Jan 25, 2022 – Proponents of the legalization of psychedelics has won a victory. ... Monday to decriminalize a wide range of activities around psychedelic drugs, ...
Psilocybin / Mescaline / Ibogaine / Ayahuasca / Iboga
-
MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022
Jan 25, 2022
-
G2 Buys Peyote-Focused Psychedelics Company Lophos Pharma | Benzinga
Jan 24, 2022 – Greenridez 2.0 Acquisitions Corp. confirmed Friday that it has completed its acquisition of psychedelic research company.
-
Cover Story: Power Trip: New York Magazine podcast investigates psychedelics | Stuff.co.nz
Jan 22, 2022 – More than ever, people are turning to psychedelics for relief, enlightenment and understanding – think ayahuasca retreats and mushroom ...
Ayahuasca
-
Have You Taken Psychedelics? Participate In The Canadian Psychedelics Survey ...
Jan 21, 2022 – ... MDMA, ayahuasca, and ketamine, as well as whether participants have ever used certain psychedelics in combination with other drugs.
MDMA / Ketamine / Ayahuasca / Psilocybin
-
G2 Acquires Lophos Pharma, a peyote focused psychedelics company - GlobeNewswire
Jan 21, 2022 – Lophos Pharma is a psychedelic research company primarily focused on novel therapeutic treatments derived from Peyote (Lophophora williamsii).
-
Do Ayahuasca Healing Ceremonies Really Work? | Psychology Today
Jan 18, 2022 – In some cases an ayahuasca ceremony may be more effective for treating neuroticism than traditional therapies. Six percent of study participants ...
Ayahuasca
-
Terminally Ill Patients In Missouri Can Seek Psychedelic Treatments Under 'Right To Try ...
Jan 15, 2022 – ... participating in the right-to-try policy to possess Schedule I drugs such as MDMA, DMT, ibogaine, LSD, mescaline, peyote and psilocybin.
Psilocybin / LSD / Mescaline / DMT / MDMA / Ibogaine / Iboga
-
Wesana Health Provides Strategic and Operational Updates
Jan 12, 2022
Wesana Health
-
Jan 12, 2022
Pharmather
-
Jan 12, 2022
MYND Life Sciences Inc.
-
Jan 12, 2022
atai Life Sciences
-
Wesana Health Granted US FDA Pre-IND Meeting for SANA-013
Jan 11, 2022
Wesana Health
-
$14.8 million for innovative mental health clinical trials
Jan 07, 2022
-
Jan 06, 2022
Field Trip Health
-
Oct 20, 2021
COMPASS Pathways
-
Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System
Oct 19, 2021
-
Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies
Oct 19, 2021
-
Oct 19, 2021
atai Life Sciences
-
Johns Hopkins Medicine Receives First Federal Grant for Psychedelic Treatment Research in 50 years
Oct 18, 2021
Johns Hopkins University
-
Oct 14, 2021
Alto Neuroscience
-
Novamind Granted DEA Licenses for Psilocybin Research
Oct 13, 2021
-
Negev Capital Invests in Production and Distribution of Artisanal Functional Mushrooms
Oct 12, 2021
-
Psygen Announces That Psilocybin from Its Patent-Pending Process Has Been Used in Human Trial
Oct 06, 2021
-
Oct 06, 2021